PLYMOUTH MEETING, Pa.,
April 15, 2020 /PRNewswire/ -- INOVIO
Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the
public health and safety concerns related to the novel coronavirus
(COVID-19) pandemic and recommendations and orders from federal and
state governmental authorities, its Annual Meeting of Stockholders
(the 2020 Annual Meeting) will now be held by means of a virtual
format only and will be held at a new time at 2:00 pm Eastern Time. The date of the meeting
(May 14, 2020), as disclosed in
INOVIO's proxy statement for the meeting, has not changed.
Online access to the meeting will begin at 1:45 pm Eastern Time. Stockholders will not be
able to attend the meeting in person. The virtual format of the
2020 Annual Meeting will provide stockholders with the same rights
and opportunities to participate as they would have at an in-person
meeting. If you plan to attend the meeting, please check
http://ir.inovio.com/investors for updates prior to the meeting
date.
As always, whether or not you plan to attend the 2020 Annual
Meeting, you are encouraged to vote your shares prior to the
meeting by one of the methods described in the proxy materials for
the meeting. If you have already voted, you do not need to vote
again.
Attending the Virtual Meeting
You can attend the meeting by accessing
www.virtualshareholdermeeting.com/INO2020 and entering the 16-digit
control number on the proxy card you previously received; if you
hold your shares in "street name" (i.e., through an account at a
broker or other nominee), please follow your broker's or nominee's
instructions you previously received to obtain your 16-digit
control number or otherwise attend through the broker or
nominee.
A list of INOVIO's stockholders of record will be available for
examination by stockholders on the meeting website during the
meeting.
Asking Questions
If you wish to submit a question, you may ask a question before
the meeting beginning at 9:00 am Eastern
Time, on April 20, 2020, and
until 11:59 pm Eastern Time, on
May 13, 2020. To submit a question,
you may log into www.proxyvote.com and enter your 16-digit control
number. Once past the login screen, click on "Question for
Management," type in your question, and click "Submit." Only
questions pertinent to meeting matters will be answered during the
meeting, subject to time constraints.
Voting Shares at the Virtual Meeting
If you have not voted your shares prior to the meeting, you will
be able to vote your shares electronically at the 2020 Annual
Meeting by clicking "Vote Here" on the meeting website. Whether or
not you plan to attend the meeting, you are encouraged to vote your
shares prior to the meeting by one of the methods described in the
proxy materials you previously received.
The proxy materials you previously received may continue to be
used to vote your shares in connection with the meeting. The
previously distributed proxy materials will not be updated to
reflect the change to a virtual format or change in time. If you
have already voted, you do not need to vote again.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat, cure, and protect
people from diseases associated with HPV, cancer, and infectious
diseases. INOVIO is the first and only company to have clinically
demonstrated that a DNA medicine can be delivered directly into
cells in the body via a proprietary smart device to produce a
robust and tolerable immune response. Specifically, INOVIO's lead
candidate VGX-3100, currently in Phase 3 trials for precancerous
cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18
in a Phase 2b clinical trial.
High-risk HPV is responsible for 70% of cervical cancer, 90% of
anal cancer, and 69% of vulvar cancer. Also in development are
programs targeting HPV-related cancers and a rare HPV-related
disease, recurrent respiratory papillomatosis (RRP);
non-HPV-related cancers glioblastoma multiforme (GBM) and prostate
cancer; as well as externally funded infectious disease DNA vaccine
development programs in Zika, Lassa fever, Ebola, HIV, and
coronaviruses associated with MERS and COVID-19 diseases. Partners
and collaborators include Advaccine, ApolloBio Corporation,
AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for
Epidemic Preparedness Innovations (CEPI), Defense Advanced Research
Projects Agency (DARPA)/DOD, GeneOne Life Science/VGXI, HIV
Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC),
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army
Institute of Research, and The Wistar Institute. INOVIO also is a
proud recipient of 2020 Women on Boards "W" designation recognizing
companies with more than 20% women on their board of directors. For
more information, visit www.inovio.com.
CONTACTS:
Investors:
Ben Matone, 484-362-0076,
ben.matone@inovio.com
Media:
Jeff Richardson, 267-440-4211,
jrichardson@inovio.com
View original
content:http://www.prnewswire.com/news-releases/inovio-to-host-its-annual-meeting-of-stockholders-in-virtual-format-and-at-a-new-time-301041372.html
SOURCE INOVIO Pharmaceuticals, Inc.